EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study

Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W Ray Kim, Leland J Yee, Craig Brooks-Rooney, Tristan Curteis, Laura J Clark, Zarena Jafry, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang und 9 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.07.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Won-Mook Choi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Viral Load, Antiviral Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain. METHODS: This multinational cohort study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in 20,826 noncirrhotic, hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with baseline HBV DNA levels ≥2000 IU/mL (3.30 log10 IU/mL) who initiated entecavir or tenofovir treatment. The primary outcome was on-treatment HCC incidence, stratified by baseline HBV viral load as a categorical variable. RESULTS: In total, 663 patients developed HCC over a median follow-up of 4.1 years, with an incidence rate of 0.81 per 100 person-years (95% confidence interval [CI], 0.75-0.87). Baseline HBV viral load was significantly associated with HCC risk in a non-linear parabolic pattern, independent of other factors. Patients with baseline viral load between 6.00 and 7.00 log10 IU/mL had the highest on-treatment HCC risk (adjusted hazard ratio, 4.28; 95% CI, 2.15-8.52; P < .0001) compared with those with baseline viral load ≥8.00 log10 IU/mL, who exhibited the lowest HCC risk. CONCLUSION: Baseline viral load showed a significant, non-linear, parabolic association with HCC risk during antiviral treatment in noncirrhotic patients with CHB. Early initiation of antiviral treatment based on HBV viral load may help prevent irreversible HCC risk accumulation in patients with CHB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicCarcinoma, HepatocellularViral LoadAntiviral AgentsLiver NeoplasmsHumansMaleFemaleMiddle AgedAdultIncidenceCohort StudiesTenofovirHepatitis B virusAgedDNA, ViralGuanineHepatitis B e AntigensRisk Assessment

Stichwörter der Autor:innen

Antiviral TreatmentHepatitis B VirusLiver CancerMultinational CohortPrevention

Substanzen

Antiviral AgentsTenofovirDNA, ViralentecavirGuanineHepatitis B e Antigens

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • CUHK Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
  • Gilead Sciences, Foster City, California.
  • Costello Medical Inc, Boston, Massachusetts.
  • Costello Medical Consulting Ltd, Cambridge, United Kingdom.

Förderung

  • Gilead Sciences Inc

Zitieren

APA

Choi, W. M., Yip, T. C., Wong, G. L., Kim, W. R., Yee, L. J., Brooks-Rooney, C., Curteis, T., Clark, L. J., Jafry, Z., Chen, C. H., Chen, C. Y., Huang, Y. H., Jin, Y. J., Jun, D. W., Kim, J. W., Park, N. H., Peng, C. Y., Shin, H. P., Shin, J. W., …, & Lim, Y. S. (2025). Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.031

Vancouver

Choi WM, Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, et al. Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.031

BibTeX
@article{Choi2025,
  author = {Choi, Won-Mook and Yip, Terry Cheuk-Fung and Wong, Grace Lai-Hung and Kim, W Ray and Yee, Leland J and Brooks-Rooney, Craig and Curteis, Tristan and Clark, Laura J and Jafry, Zarena and Chen, Chien-Hung and Chen, Chi-Yi and Huang, Yi-Hsiang and Jin, Young-Joo and Jun, Dae Won and Kim, Jin-Wook and Park, Neung Hwa and Peng, Cheng-Yuan and Shin, Hyun Phil and Shin, Jung Woo and Yang, Yao-Hsu and Lim, Young-Suk},
  title = {Baseline Viral Load and On-Treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.07.031}
}
Kostenlos starten →